Doc Payments For Coronary Stenting Will Drop Next Year, But Will Better Reflect Procedure Complexity
This article was originally published in The Gray Sheet
New coding structure for coronary stenting recognizes more complex procedure with higher levels of Medicare reimbursement, but overall physician payments for percutaneous coronary interventions will go down in 2013.
You may also be interested in...
ASTRO proposes redesign of key radiation therapy codes as first part of its Payment Reform Action Plan.
Long used to a growing market driven by favorable demographics, cardiovascular companies are facing a declining PCI market, in the US and Europe at least, and are forced to shift their strategies to adapt. Volcano, for one, is articulating a new way to approach this declining market.
With a total market potential estimated in the multibillion-dollar range, the drug-coated balloon opportunity is attracting a growing list of competitors, including several leading multinational cardiovascular device companies that have entered the space via recent acquisitions. DCBs still need to prove their worth in large, long-term clinical trials, but the ultimate proving point for DCBs could center on cost: if they can offer an effective treatment option that is significantly less expensive than existing devices, DCBs may provide a compelling economic argument.